{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:09:11Z","timestamp":1792202951987,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":1155,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["NHS 2011T012"],"award-info":[{"award-number":["NHS 2011T012"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/09506\u20105"],"award-info":[{"award-number":["2017\/09506\u20105"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1111\/jth.14364","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T07:10:58Z","timestamp":1545203458000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial"],"prefix":"10.1016","volume":"17","author":[{"given":"Fernanda A.","family":"Orsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.H.A.","family":"Kruip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits R.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Hylckama Vlieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mettine H.A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.","family":"Lijfering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14364_bb0010","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the global disease burden","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1111\/jth.14364_bb0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14364_bb0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474086.2016.1245137","article-title":"Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility","volume":"9","author":"Lijfering","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1111\/jth.14364_bb0030","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","article-title":"Statins and primary prevention of venous thromboembolism: a systematic review and meta\u2010analysis","volume":"4","author":"Kunutsor","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14364_bb0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.thromres.2011.05.012","article-title":"Statins in the prevention of venous thromboembolism: a meta\u2010analysis of observational studies","volume":"128","author":"Pai","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14364_bb0040","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database","volume":"340","author":"Hippisley\u2010Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/jth.14364_bb0045","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14364_bb0050","doi-asserted-by":"crossref","first-page":"e1001310","DOI":"10.1371\/journal.pmed.1001310","article-title":"Effect of statins on venous thromboembolic events: a meta\u2010analysis of published and unpublished evidence from randomised controlled trials","volume":"9","author":"Rahimi","year":"2012","journal-title":"PLoS Med"},{"key":"10.1111\/jth.14364_bb0055","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/eurheartj\/ehx107","article-title":"Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies","volume":"38","author":"Kunutsor","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.14364_bb0060","doi-asserted-by":"crossref","first-page":"e1001311","DOI":"10.1371\/journal.pmed.1001311","article-title":"Statins and venous thrombosis: a story too good to be true?","volume":"9","author":"Rosendaal","year":"2012","journal-title":"PLoS Med"},{"key":"10.1111\/jth.14364_bb0065","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/eurheartj\/ehy014","article-title":"Rosuvastatin use improves measures of coagulation in patients with venous thrombosis","volume":"39","author":"Biedermann","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.14364_bb0070","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.12223","article-title":"Statin therapy and levels of hemostatic factors in a healthy population: the Multi\u2010Ethnic Study of Atherosclerosis","volume":"11","author":"Adams","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1160\/TH14-11-0937","article-title":"Association between statin use and plasma D\u2010dimer levels. A systematic review and meta\u2010analysis of randomised controlled trials","volume":"114","author":"Sahebkar","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0080","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1160\/th15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta\u2010analysis of randomised placebo\u2010controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1160\/TH09-06-0356","article-title":"Thrombin generation as an intermediate phenotype for venous thrombosis","volume":"103","author":"Segers","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/TH08-02-0099","article-title":"Thrombin generation in patients after acute deep\u2010vein thrombosis","volume":"100","author":"ten Cate\u2010Hoek","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"Dielis","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thromres.2011.10.017","article-title":"Thrombin generation in clinical conditions","volume":"129","author":"Ten Cate","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14364_bb0105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1111\/jth.14364_bb0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2141.2008.07267.x","article-title":"Thrombin generation testing in routine clinical practice: are we there yet?","volume":"142","author":"van Veen","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14364_bb0115","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/j.1538-7836.2005.01249.x","article-title":"The plasma hemostatic proteome: thrombin generation in healthy individuals","volume":"3","author":"Brummel\u2010Ziedins","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1309\/AJCPQ2NJD3PXFTUG","article-title":"Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay","volume":"143","author":"Morishima","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/jth.14364_bb0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH08-03-0141","article-title":"Assessment of thrombin generation II: validation of the Calibrated Automated Thrombogram in platelet\u2010poor plasma in a clinical laboratory","volume":"100","author":"Spronk","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0130","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1373\/clinchem.2008.112243","article-title":"Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D\u2010dimer","volume":"54","author":"Eichinger","year":"2008","journal-title":"Clin Chem"},{"key":"10.1111\/jth.14364_bb0135","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jth.13043","article-title":"The risk of a first and a recurrent venous thrombosis associated with an elevated D\u2010dimer level and an elevated thrombin potential: results of the THE\u2010VTE study","volume":"13","author":"van Hylckama Vlieg","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"Hron","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/jth.14364_bb0145","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2008.03117.x","article-title":"High rate of unprovoked recurrent venous thrombosis is associated with high thrombin\u2010generating potential in a prospective cohort study","volume":"6","author":"Besser","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0150","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/j.1538-7836.2009.03561.x","article-title":"Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study","volume":"7","author":"Lutsey","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0155","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1538-7836.2008.03018.x","article-title":"High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism","volume":"6","author":"Tripodi","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2007.06738.x","article-title":"Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence","volume":"138","author":"van Hylckama Vlieg","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14364_bb0165","doi-asserted-by":"crossref","first-page":"8227","DOI":"10.1073\/pnas.85.21.8227","article-title":"Enhanced thrombin generation and platelet binding on herpes simplex virus\u2010infected endothelium","volume":"85","author":"Visser","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.14364_bb0170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1538-7836.2005.01270.x","article-title":"Anti\u2010protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation","volume":"3","author":"Regnault","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0175","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0735-1097(99)00023-6","article-title":"Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia","volume":"33","author":"Szczeklik","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.14364_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0037-1613151","article-title":"Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study","volume":"88","author":"Cortellaro","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0185","doi-asserted-by":"crossref","first-page":"e32894","DOI":"10.1371\/journal.pone.0032894","article-title":"Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial","volume":"7","author":"Macchia","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.14364_bb0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02982799","article-title":"Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components","volume":"76","author":"Ural","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1111\/jth.14364_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","article-title":"The dynamics of thrombin formation","volume":"23","author":"Mann","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"10.1111\/jth.14364_bb0200","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0049-3848(12)70008-7","article-title":"Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients","volume":"129","author":"Ay","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14364_bb0205","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/jth.13337","article-title":"Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case\u2010control study","volume":"14","author":"Martinez","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0038-1648843","article-title":"Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants\u2013a prospective study","volume":"72","author":"Palareti","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0215","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.14364_bb0220","first-page":"392","article-title":"Anticoagulant effects of statins and their clinical implications","volume":"111","author":"Undas","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14364_bb0225","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.14364_bb0230","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid\u2010lowering therapy","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.14364_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2012.10.011","article-title":"Data management in thrombin generation","volume":"131","author":"Hemker","year":"2013","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14364_bb0240","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open\u2010label, phase 2\/3, non\u2010inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14364_bb0245","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jth.14364_bb0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"Kintigh","year":"2018","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622024679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622024679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:23:56Z","timestamp":1761535436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622024679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1538783622024679"],"URL":"https:\/\/doi.org\/10.1111\/jth.14364","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The Authors. Journal of Thrombosis and Haemostasis. Published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}